Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25p -3.23% 7.50p 7.00p 8.00p 7.75p 7.50p 7.75p 0 09:56:27
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.4 -3.1 - 6.85

Synairgen Share Discussion Threads

Showing 601 to 622 of 625 messages
Chat Pages: 25  24  23  22  21  20  19  18  17  16  15  14  Older
DateSubjectAuthorDiscuss
19/6/2017
21:24
Bought another 20k today at 8.5p Lets say cash is around 3m£ that leaves EV at 4.5m£ which is just too low in spite of all the setbacks recently . We are expecting news on INFB by mid July latest as per the finncap note above . They are not in a good place as regards raising cash /implied dilution but they are so undervalued at 8p odd I think a bid cannot be discounted.And Woodford would be up for that i think.
ohisay
18/5/2017
08:05
Thanks ohisay, that's helpful and strengthens my resolve to hang on. It looks like they are going to be looking at beta-interferon for COPD now, which seems to makes commercial sense assuming the science stacks up. I wonder what the IP position is on COPD, especially given that Faron's active interest in beta-interferon for ADRS? I will ask the question when I get a chance.
timbo003
18/5/2017
03:56
http://www.proactiveinvestors.co.uk/companies/news/177900/synairgen-pleased-with-the-progress-made-with-the-loxl2-programme-177900.html House broker finnCap said the cash position was some £1.2mln higher than expected, which it put down to lower research & development costs, which were timing related, and better than expected working capital. “As indicated in late April, Synairgen intends to conduct a thorough analysis of all data arising from the AZ Phase IIa study with the intention of providing an update in the next 1-2 months. The possibility of using inhaled Interferonbeta (IFN-beta) in COPD, given recently published data indicating the link between colds and exacerbations in COPD, suggests the analysis to be warranted,” opined finnCap. “Target price remains under review, pending outcome of analysis,” finnCap revealed. “Suffice to say, the progress of LOXL2 into Phase I is a valuation inflection point in itself, worth as much as 5-10p per share but excluding any upfront payments,” it added.
ohisay
17/5/2017
08:23
Not a bad update this morning I thought particularly in the ifnb area.. Bought 20k at 10.75p - looks a tad cheap to me. Furthermore on an objective measure we saw that treatment with inhaled IFN-beta resulted in an improved morning peak expiratory flow of 19.7L/min (p=0.01). The day-by-day changes in this parameter closely mirror the changes we observed in our Phase II study. Once again inhaled IFN-beta was well tolerated. ... We are particularly interested in using inhaled IFN-beta in COPD. Two new publications(1,2) in 2017 have shown that cold viruses are highly likely to cause exacerbations in COPD, which contrasts with the findings in asthma from the INEXAS trial, where only around 10% of patients exacerbated during cold infections. There is also a greater clinical need in COPD compared to asthma as exacerbations in COPD patients are linked to a rapid and permanent deterioration of disease and death. New technology has recently emerged which will enable us to confirm viral infection prior to commencing treatment, making trial management and interpretation easier. Thus the new data linking viruses to exacerbations, a better understanding of the underlying biology in COPD, the high clinical need, and new diagnostic technology presents us with an attractive opportunity to explore the drug's full potential.
ohisay
05/5/2017
14:49
the 3 year share price graph looks tragic!! i followed neil woodford in but thankfully left with a small loss....
nakedsteve
05/5/2017
13:08
The short answer is Yes ! Putting the current issues regarding the results of the Astra P11 Clinical trial to one side..the following from the SNG latest Presentation (March 2017) is very interesting...and subject to successful completion of Toxicology testing .. Phase I clinical trials scheduled to start in H2 2017.. Whilst again no Guarantee's of success here can be taken it is worth looking at the potential .. and it is significant of revenue that could be earned by SNG's involvement ... The slide below gives details of deals around Fibrosis struck with Pharma Majors. They are very significant in monetary terms... It is worth I believe remaining on the bus to see the outcome of SNG Fibrosis journey.. For those wanting to see the full presentation.. hxxp://www.synairgen.com/media/1346/introduction-to-synairgen-march-2017v2.pdf Develop an anti-fibrotic LOXL2 inhibitor for Idiopathic Pulmonary Fibrosis (IPF) • High LOXL2 is associated with more rapid disease progression • Recent deal in Fibrosis include: o Discovery stage  Boehringer Ingelheim 2016 collaboration with Inventiva to develop targets for IPF. Deal value up to €170m plus tiered royalties o Phase I  Gilead buys Nimbus Therapeutics in 2016 for Liver fibrosis programme $0.4bn up front and up to $0.8bn future payments o Phase II  Allergan buys Tobira Therapeutics in 2016 for Liver fibrosis programme $0.6bn up front and up to $1.1bn future payments  Bristol-Myers Squibb enters an agreement in 2015 providing exclusive rights to acquire Promedior Inc for up to $1.25bn o Post approval  Roche acquired Intermune in 2014 for $8bn, main programme was pirfenidone for IPF, and other anti-fibrosis programmes
rosejs2
05/5/2017
12:25
is there any hope for synairgen?
nakedsteve
28/4/2017
14:03
If Woodford puts up any more cash - rather than cutting and running could well be in high coupon preference shares with blocking rights possibly similar to those used to further fund RM2 - but with all his problems with health development coys such as Allied Minds he might/should let them die.
pugugly
28/4/2017
13:19
I think the board needs to provide some more information. What were the preset criteria AZ used to assess the drug and was it able to meet them given the early halt to the trial? There's a big difference between bad data and too little data.Regardless, it's bad news. At a minimum, Synairgen has lost three years on the interferon, since any new partner will surely want a new P2. I agree with the comment above that it's now tainted and it'll be hard to find another partner, even if the science is still reasonably positive.
mirako
28/4/2017
10:57
MMS got this by the goolies people. They offloaded those 3.6m shs at 7p to punters above 13p. Don't leave much to the imagination what they are going to do now, compounding with the facts a fund raising will happen and high probability biggies will start cutting the holdings.
big bear billy
28/4/2017
08:20
Cash call at 6p, but they need to fast though. Sp is surely heading towards 10p now.
duck_and_dive
28/4/2017
07:14
That announcement yesterday morning was not entirely surprising. I think they will struggle to find another taker for the interferon program. They have enough cash to complete their LOXL2 commitments, but presumably not beyond. With a market cap of just £12, what next? Woodford will no doubt have a big say in the future direction, but I suspect a cash call will be involved somewhere along the line. Oh joy!
timbo003
27/4/2017
12:06
my old friend glencut, you're never far from bad news and shti stirring!
nakedsteve
27/4/2017
11:28
Is the 😼 Alive or 🙀 Die mmmmm! Any thoughts on tomorow🤔
glenkaz
27/4/2017
11:04
Careful Mr Glenkaz, there could be more II selling, they need money. Read the RNS, today intraday dead cat bounce is over I think.
big bear billy
27/4/2017
11:03
Really unfortunate for that sell. Right issue at 7p? They better be quick, otherwise could be begging bowl with Darwin, Henderson or Crede. What about more biggies running with their pants down here, in the background?
big bear billy
27/4/2017
10:24
13.5 sell 14.75 buy 👺👹 mm's taking the p/ss!! Gla! 😋
glenkaz
27/4/2017
10:02
It might have been Leonard Licht who held 3,700,000 throwing in the towel.
rosejs2
27/4/2017
10:00
Could rise to 15p-16p now.
big bear billy
27/4/2017
09:58
A 950K holding (worth yesterday) sold at 7p for 255K
big bear billy
27/4/2017
09:56
Deary me Someone got liquidated here. 3.6m @ 7.00p. very harsh.
big bear billy
27/4/2017
09:07
plenty of lumpy buying at 13.5p which was just about its previous low point in december.
ohisay
Chat Pages: 25  24  23  22  21  20  19  18  17  16  15  14  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170727 22:53:21